first drug to treat radiation sickness approved
Last Updated : GMT 09:40:38
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
Last Updated : GMT 09:40:38
Themuslimchronicle, themuslimchronicle

First drug to treat radiation sickness approved

Themuslimchronicle, themuslimchronicle

Themuslimchronicle, themuslimchronicleFirst drug to treat radiation sickness approved

Drug to treat radiation
Tehran - FNA

New research has led to FDA approval of the use of a drug to treat the effects of radiation exposure following a nuclear incident. The drug, Neupogen, is the first ever approved for the treatment of acute radiation injury.

The research was done by Thomas J. MacVittie, PhD, professor, and Ann M. Farese, MA, MS, assistant professor, both in the University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology's Division of Translational Radiation Sciences. The investigators did their research in a non-human clinical model of high-dose radiation.

"Our research shows that this drug works to increase survival by protecting blood cells," said Dr. MacVittie, who is considered one of the nation's leading experts on radiation research. "That is a significant advancement, because the drug can now be used as a safe and effective treatment for the blood cell effects of severe radiation poisoning."

Radiation damages the bone marrow, and as a result decreases production of infection-fighting white blood cells. Neupogen® counteracts these effects. The drug, which is made by Amgen, Inc., was first approved in 1991 to treat cancer patients receiving chemotherapy. Although doctors may use it "off label" for other indications, the research and the resulting approval would speed up access to and use of the drug in the event of a nuclear incident.

This planning is already under way. In 2013, the Biomedical Advanced Research and Development Authority (BARDA), an arm of the Department of Health and Human Services, bought $157 million worth of Neupogen® for stockpiles around the country in case of nuclear accident or attack.

Neupogen® is one of several "dual-use" drugs that are being examined for their potential use as countermeasures in nuclear incidents. These drugs have everyday medical uses, but also may be helpful in treating radiation-related illness in nuclear events. Dr. MacVittie and Ms. Farese are continuing their research on other dual-use countermeasures to radiation. They are now focusing on remedies for other aspects of radiation injury, including problems with the gastrointestinal tract and the lungs.

The research builds on 40 years of work that Dr. MacVittie and his team have conducted in the field of radiation research, during which they have helped to define the field. The Neupogen study is also part of a broad portfolio of research being conducted by faculty in the Department of Radiation Oncology. Among these are Minesh Mehta, MD, the medical director of the Maryland Proton Treatment Center, who is focusing on research into thoracic oncology, neuro-oncology, integrating imaging advances with radiation therapy, and innovative applications of new radiation therapy technologies to test biological concepts. Another researcher in the department is Zeljko Vujaskovic, MD, PhD, director of the Division of Translational Radiation Sciences; he is doing research on identifying potential biomarkers predicting individual patient risk for injury, and to develop novel therapeutic interventions/strategies to prevent, mitigate, or treat radiation injury.

"In terms of both research and treatment, our department is leading the way in developing the most effective discovery-based clinical applications to help protect and heal patients," says William F. Regine, MD, professor and Isadore & Fannie Schneider Foxman Endowed Chair in Radiation Oncology at the UM SOM.

He added that research has served as the foundation for the Department of Radiation Oncology's recent development of four clinical modalities for the treatment of cancer through radiation:

• Proton Treatment, a precise approach to cancer, which targets tumors while minimizing harm to surrounding tissues. Proton treatment uses protons traveling at about two-thirds the speed of light to precisely deliver beams of radiation to the tumor. This treatment will be available in the new 110,000 sq ft Maryland Proton Treatment Center before the end of the year;

• Selective Internal Radiation Therapy, a precision modality for treating patients with particularly difficult to remove tumors involving the liver such as those from colorectal cancers;

• Gammapod, a new, high-precision, noninvasive method of treating early-stage breast cancer;

• Thermal Therapies, the use of "heat" in treating a broad spectrum of malignancies.

themuslimchronicle
themuslimchronicle

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

first drug to treat radiation sickness approved first drug to treat radiation sickness approved

 



Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle

GMT 21:49 2018 Tuesday ,23 January

Trump to tell Erdogan of concern over Syria offensive

GMT 08:26 2018 Tuesday ,23 January

Five things to know about Davos

GMT 16:13 2018 Sunday ,14 January

Netanyahu urges Macron to 'fix' Iran nuclear deal

GMT 10:17 2016 Thursday ,21 January

WHO confirms second new Ebola case in Sierra Leone

GMT 13:33 2011 Wednesday ,06 July

Russia bids to expand Arctic border to seek gas

GMT 09:06 2011 Wednesday ,21 September

Powerful typhoon hits Japan

GMT 11:15 2011 Wednesday ,03 August

2 glaciers in Nepal to disappear

GMT 19:01 2017 Saturday ,19 August

Finland suspect an asylum seeker, targeted women

GMT 02:45 2017 Wednesday ,08 February

Coup defeat a matter of time, says Yemeni VP

GMT 17:38 2017 Friday ,14 July

Saad Lamjarred denied issuance of new song

GMT 16:02 2011 Thursday ,21 April

Chelsea squad not good enough

GMT 11:29 2011 Tuesday ,19 July

Etihad Towers on track for delivery

GMT 02:05 2017 Wednesday ,22 February

UAE takes keen interest in supporting higher education

GMT 07:17 2017 Saturday ,01 July

Key US inflation measure declines in May
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
 
 Themuslimchronicle Facebook,themuslimchronicle facebook  Themuslimchronicle Twitter,themuslimchronicle twitter Themuslimchronicle Rss,themuslimchronicle rss  Themuslimchronicle Youtube,themuslimchronicle youtube  Themuslimchronicle Youtube,themuslimchronicle youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©

muslimchronicle muslimchronicle muslimchronicle muslimchronicle
themuslimchronicle themuslimchronicle themuslimchronicle
themuslimchronicle
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
themuslimchronicle, themuslimchronicle, themuslimchronicle